Search Results - "O’Donovan, N."

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer by Corkery, B., Crown, J., Clynes, M., O'Donovan, N.

“…No proven targeted therapy is currently available for the treatment of triple-negative breast cancer (TNBC). Epidermal growth factor receptor (EGFR) is…”
Get full text

Src: a potential target for the treatment of triple-negative breast cancer by Tryfonopoulos, D., Walsh, S., Collins, D.M., Flanagan, L., Quinn, C., Corkery, B., McDermott, E.W., Evoy, D., Pierce, A., O’Donovan, N., Crown, J., Duffy, M.J.

“…Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2)…”
Get full text

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer by Eustace, A. J., Madden, S. F., Fay, J., Collins, D. M., Kay, E. W., Sheehan, K. M., Furney, S., Moran, B., Fagan, A., Morris, P. G., Teiserskiene, A., Hill, A. D., Grogan, L., Walshe, J. M., Breathnach, O., Power, C., Duke, D., Egan, K., Gallagher, W. M., O’Donovan, N., Crown, J., Toomey, S., Hennessy, B. T.

“…Background Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete…”
Get full text

Long-term dietary intake from infancy to late adolescence is associated with gut microbiota composition in young adulthood by Oluwagbemigun, Kolade, O’Donovan, Aoife N, Berding, Kirsten, Lyons, Katriona, Alexy, Ute, Schmid, Matthias, Clarke, Gerard, Stanton, Catherine, Cryan, John, Nöthlings, Ute

“…Gut microbiota composition as influenced by long-term diet may be associated with the risk of adult chronic diseases. Thus, establishing the relation of…”
Get full text

Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer? by Synnott, N.C., Murray, A., McGowan, P.M., Kiely, M., Kiely, P.A., O'Donovan, N., O'Connor, D.P., Gallagher, W.M., Crown, J., Duffy, M.J.

“…The identification and validation of a targeted therapy for patients with triple‐negative breast cancer (TNBC) is currently one of the most urgent needs in…”
Get full text

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines by Collins, D.M., O'Donovan, N., McGowan, P.M., O'Sullivan, F., Duffy, M.J., Crown, J.

“…Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by CD56 + natural killer (NK) cells may contribute to the activity of trastuzumab in…”
Get full text

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells by Caiazza, F, McGowan, P M, Mullooly, M, Murray, A, Synnott, N, O'Donovan, N, Flanagan, L, Tape, C J, Murphy, G, Crown, J, Duffy, M J

“…Background: Identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), that is, breast cancers negative for oestrogen…”
Get full text

HER2-targeted antibody dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells against tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines by Collins, D.M., Gaynor, N., Conlon, N.T., O’Donovan, N., Crown, J.P.

Get full text

HER-2 signaling and inhibition in breast cancer by Browne, B C, O'Brien, N, Duffy, M J, Crown, J, O'Donovan, N

“…Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and…”
Get more information

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells by Browne, B.C., Crown, J., Venkatesan, N., Duffy, M.J., Clynes, M., Slamon, D., O'Donovan, N.

“…Background: Although trastuzumab has improved the prognosis for HER-2-positive breast cancer patients, not all HER-2-positive breast tumours respond to…”
Get full text

Pharmacist-driven multidisciplinary pretreatment workup process for hepatitis C care: A novel model for same-day pretreatment workup by Houck, Kelly K., Ifeachor, Amanda P., Fleming, Breanne S., Andres, Audrey M., O’Donovan, Kristin N., Johnson, Andrew J., Liangpunsakul, Suthat

“…The objective is to describe and quantify the impact of a novel practice model for pharmacist involvement in care coordination and patient education in…”
Get full text

Nasal endoscopy and paranasal sinus computerised tomography (CT) findings in an Irish cystic fibrosis adult patient group by Casserly, P., Harrison, M., O’Connell, O., O’Donovan, N., Plant, B. J., O’Sullivan, P.

“…Cystic fibrosis (CF) is a common inherited disorder in Caucasians in Ireland having the highest reported incidence. CF has well-recognised clinical sequelae in…”
Get full text

ADAM-17: a novel therapeutic target for triple negative breast cancer by McGowan, P.M., Mullooly, M., Caiazza, F., Sukor, S., Madden, S.F., Maguire, A.A., Pierce, A., McDermott, E.W., Crown, J., O'Donovan, N., Duffy, M.J.

“…Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2…”
Get full text

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma by MAHGOUB, T, EUSTACE, A.J, COLLINS, D.M, WALSH, N, O'DONOVAN, N, CROWN, J

“…Despite recent advances in targeted therapies and immunotherapies metastatic melanoma remains only rarely curable. The objective of the present study was to…”
Get full text

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines by Collins, D. M., Crown, J., O’Donovan, N., Devery, A., O’Sullivan, F., O’Driscoll, L., Clynes, M., O’Connor, R.

“…Summary To investigate the interactions of Epidermal Growth Factor Receptor (EGFR)-inhibiting tyrosine kinase inhibitors (TKIs) on P-gp-mediated drug…”
Get full text

238 Chromosomal instability in cancer and immune-related genes by Madden, S.F, Collins, D.M, Gaynor, N, Gallagher, W.M, O'Donovan, N, Crown, J

Get full text

239 Tyrosine kinase inhibitors (TKIs) enhance response to HER2 targeted antibodies by Ivers, L, Collins, D, Canonici, A, Gullo, G, O'Donovan, N, Crown, J

Get full text

Prion Protein Fragment PrP-(106–126) Induces Apoptosis via Mitochondrial Disruption in Human Neuronal SH-SY5Y Cells by O'Donovan, Conor N., Tobin, Deirdre, Cotter, Thomas G.

“…The synthetic peptide PrP-(106–126) has previously been shown to be neurotoxic. Here, for the first time, we report that it induces apoptosis in the human…”
Get full text

304 Notch in Breast Cancer: Preclinical and Clinical Studies by McGowan, P.M, McDermott, E.W, Crown, J, O'Donovan, N, Duffy, M.J

Get full text

Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer by RYAN, B, O'DONOVAN, N, BROWNE, B, O'SHEA, C, CROWN, J, HILL, A. D. K, MCDERMOTT, E, O'HIGGINS, N, DUFFY, M. J

“…Alternative splicing of survivin mRNA gives rise to multiple isoforms, that is, survivin and 3 splice variants, survivin-2B, survivin-3B and survivin- Delta…”
Get full text